Wedelolactone Ameliorates Ischemic Stroke by Inhibiting Oxidative Damage and Ferroptosis via HIF-1α/SLC7A11/GPX4 Signaling
Our discovery revealed that the Wel could alleviate IS by inhibiting oxidative damage and ferroptosis via HIF-1α/ SLC7A11/GPX4 signaling pathway. Wel may represent a promising active compound for anti-IS, while also providing novel insights into the elucidation of its molecular mechanisms and potential clinical implications.
Authors
- Ruili Li (ORCID: https://orcid.org/0000-0001-5112-3201)
- Meina Zhao (ORCID: https://orcid.org/0009-0000-1645-6684)
- Xingru Tao
- Fei Mu (ORCID: https://orcid.org/0000-0001-5706-8864)
- Wangting Li (ORCID: https://orcid.org/0000-0001-7070-5768)
- Kai Gao (ORCID: https://orcid.org/0000-0002-0771-7755)
- Rui Lin (ORCID: https://orcid.org/0000-0002-3846-9301)
- Dong Xu (ORCID: https://orcid.org/0000-0002-8871-9006)
- Chao Guo (ORCID: https://orcid.org/0000-0003-2259-0788)
- Wei Zhang (ORCID: https://orcid.org/0000-0001-7016-4922)
- Jingwen Wang (ORCID: https://orcid.org/0000-0002-3450-9046)
Institutions
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/dddt.s528831
- Citations
- 2
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.87